

Industry-Leading Anti-Idiotypic Antibody Discovery Services

Delivering high-quality anti-idiotype antibodies using our DiversimAb™ platform.



THE ABVERIS ADVANTAGE:

125+ PROJECTS COMPLETED

ULTRA-RAPID PREDICTABLE TIMELINES

FLEXIBLE DELIVERABLES

HYBRIDOMA & B CELL WORKFLOWS

ANTI-IDS: CRITICALLY IMPORTANT REAGENTS

Biotherapeutic detection reagent development is often on your critical path for timely clinical trial execution. Each target and end application need is unique just like your biotherapeutic molecule. De-risk your reagent development by working with an experienced discovery partner who understands what's at stake.

With over 125+ successful anti-idiotype discovery projects under our belt, Abveris has crafted a custom-tailored anti-idiotype antibody discovery platform that offers hybridoma and single B cell workflows to fit diverse assay applications (PK, ADA, and beyond) with rapid, predictable discovery timelines.

ADVANCED SCREENING CAPABILITIES

- Serum matrix testing
- Blocking/non-blocking screening
- Antibody pair identification
- Informed affinity assessments
- On-cell binding & receptor occupancy

INDUSTRY-LEADING TECHNOLOGIES




sartorius

HAMILT@N°



FORTÉBIO





Rigorously Qualified, Assay-Ready Monoclonal Antibody Reagents for increasingly diverse, anti-id assay applications



Our anti-id guarantee promises delivery of anti-idiotypic antibodies capable of specific binding to the target biologic in the presence of human serum. If we don't find at least one, we will perform an additional screen for FREE.



Industry-Leading Anti-Idiotypic Antibody Discovery Services



Delivering high-quality anti-idiotype antibodies using our DiversimAb™ platform.

Rapid Hybridoma & Ultra-Rapid B Cell Workflows

ULTRA-RAPID B CELL SCREENING

Timeline to final delivery & guaranteed supply: 10-12 weeks

Antigen & Assay Preparation

Ontions for Fab digestion, antigen production, and custom assay development

Immunization protocols tuned to your affinity and speed requirements

Beacon® Screening & Ab Seguencing

Specificity and blocking screening on proteins and cells + antibody sequencing 10K+ B cells screened

Antibody Production & **Vector Delivery**

Transient mammalian Ah production + vector transfer available

Advanced Antibody Screening

Rank affinity, blocking, and pairing profiles by Octet BLI, Carterra SPR, ELISA, FACS

Benefits:

Fastest speed for aggressively tight timelines

Reliable & sensitive screening = precision in candidate selection

4-6 weeks to Ab sequences, 10-12 weeks to purified Ab supply

☑ Direct access to experienced project management

HYBRIDOMA

Timeline to Ab sequences & samples for partner validation: 10-12 weeks

Timeline to final delivery & guaranteed antibody supply: 14-16 weeks

Antigen & Assay Preparation

Options for Fab digestion, antigen production, and custom assay developmen

Benefits:

Immunization protocols tuned to your affinity and

Industry-leading screening package

Highly diverse & highly qualified Ab deliverables

✓ Direct access to experienced project management

10-12 weeks to Ab sequences, 14-16 weeks to purified Ab supply

ELISA or flow cytometry, vigorous counter-screening and serum matrix testing

Advanced Antibody Screening

Rank affinity, blocking, and pairing profiles by Octet BL Carterra SPR, flow cytomet

Fastest project path: rapid, economical 96-throughput antibody sequencing

Transient mammalian Ab production + vector transfer available

Generate stable production cell lines with sequence for Partner's selected clones

Scale, purify, and validate antibody produced from hybridoma cell line culture

Partner Validation Testing

Optional confirmation

TESTIMONIALS

We asked our repeat partners: what makes our anti-idiotype antibody offerings special?

"I can always trust that I'll have no surprises when I'm working with the Abveris team, and that's why I continue to come back. I've outsourced dozens of anti-id programs during my career and there have been too many times where simple oversights have cost me 6+ months in assay development. For these high-impact translational programs, it's critical we get it right the first time."

- Director of Translational Development at Biopharma

"At Promega, we struggled to acquire a high-affinity, high-specificity antibody against one target of interest. After failing with two previous vendors, we enlisted the help of Abveris and their DiversimAb approach, and we soon had a multitude of high-quality clones to choose from. We eventually chose a clone that far exceeded our expectations for performance. We were continually impressed by their high-quality analytical data, excellent communication, and overall collaborative spirit."

- Promega Corporation